Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026GlobeNewsWire • 08/06/26
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.GlobeNewsWire • 08/06/26
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH TrialGlobeNewsWire • 06/30/26
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®GlobeNewsWire • 06/26/26
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?Zacks Investment Research • 06/26/26
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with HypoparathyroidismGlobeNewsWire • 06/13/26
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with HypoparathyroidismGlobeNewsWire • 06/11/26
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026GlobeNewsWire • 06/08/26
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)Seeking Alpha • 05/28/26
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 YearsGlobeNewsWire • 05/06/26
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026GlobeNewsWire • 04/30/26
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028GlobeNewsWire • 04/21/26
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on NasdaqGlobeNewsWire • 04/20/26
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with AchondroplasiaGlobeNewsWire • 04/08/26